FDA Oncology Tools web site 'GD' (CE AJ EHB9 '/'1) 'D'/HJ) H 'D'79E) 'DE9FJ) ('D317'F

G/' 'DEHB9 J-*HJ 9DI E9DHE'* E*FH9) 9F 'D'E1'6 'D317'FJ) H 'D'/HJ) 'DE51- '3*./'EG' AJ 9D',G'. JECFC E1',9) 'DE9DHE'* GF'. 'F*BJ 9FH'F' EF *DC 'DEH,H/) 'DI J3'1C 'H EF 'DEH'5A'* 'DEH,H/) 'DI '3AD. G/' 'DEHB9 JE+D E-'HD) 'HDJ) D,E9 H *B/JE 'DE9DHE'* -3( FH9 'DE16 'D317'FJ. G/' 'DEHB9 E41H9 ,/J/ FB/EG H 3FB/1 ED'-8'*CE 9DJG. 3F3*./E ED'-8'*CE D*-3JF G/' 'DEHB9 H 1(E' D*7(JB E+DG AJ 'E1'6 '.1I 

   ED'-8'*CE 

  Approved Oncology Drugs  '/HJ) E51- '3*./'EG'

E9DHE'* 9F '/HJ) E51- '3*./'EG' AJ 'E1'6 317'FJ) E9JF)

9F'HJF DD'/HJ), ED.5'* B1'1'* 'D*51J- H F5'!- 9F '3*./'E '/HJ) :J1

E51- (G' H CJAJ) 'D-5HD 9DJG'  

 Disease Summaries ED.5'* DD'E1'6

5D'* 'DI E5'/1 E9DHE'* 9F 'E1'6 317'FJ) E9JF) H B'EH3 DD317'F

Regulatory Tools '/H'* ',1'!J)

J5A CJAJ) *51J- 'D'/'1) DD'/HJ), 'F4'!'* 'D'/'1) 'DE9FJ) ('D317'F H

EH'6J9 ',1'!J) '.1I. J-*HJ 'J6' 9DI B'EH3 ',1'!J ,1H2F'E)

',*E'9'* D,F) 'D'/HJ) 'D317'FJ),  '14JA HB'!9 ',*E'9'* G/G 'DD,F) H'DH+'!B 'D'14'/J) DD'/'1)   

Oncology Reference Tools '/H'* 'DE1',9) AJ 'D317'F

   '/H'* DD*4.J5, D*BHJE 'D-'D) 'D9'E) DDE1J6, D9H'16 'D'/HJ) H 

 'F8E) D'-5'! H *B/J1 'D,19) AJ 'D'F3'F H 'D-JH'F

Patient Liaison Program E41H9 'DE9DHE'* DDE16I 

E9DHE'* EF EC*( 'D'/'1) DD5-) 9F E4'1J9 'D'/'1) DDE16I H D'!-) ('D*,'1( 'D31J1J) 'D7(J)

Additional Resources  E5'/1 '6'AJ)

5D'* DE9DHE'* ',1'!J) H E9DHE'* 9F 'E1'6 'D317'F

EFG' 'D*,'1( 'D31J1J) 'D7(J), 'DE,D'* 'D9DEJ), E1'C2 7(J), 'DE9G/ 'DBHEJ DD317'F H E5'/1

'.1I DDE9DHE'*

Centers and Divisions  E1'C2 H 'B3'E '/'1) 'D'/HJ) H 'D'79E) 

5D'* DE1'C2 H 'B3'E 'D'/'1) 'D*J DG' E3$HDJ'* 9F 'DEF*H,'* 'DE9FJ) ('D317'F

F1-(   (ED'-8'*CE  9DI G/' 'DEHB9

FDA/Center for Drug Evaluation and Research
Last Updated: 
Originator: OTCOM/DLIS
HTML by  SH

Arabic Translation by Ramzi Dagher, MD
Reviewed by Safaa Ibrahim, PhD